The Regimen for Expanding Buprenorphine Access: Collaborative Pharmacy-based Induction

In 2022, the opioid crisis claimed over 100,000 lives. Expanding access to medication assisted substance use disorder treatment has never been so critical. Now, with the DEA X-waiver eliminated, the opportunity to provide life saving treatment is that much easier. This week The Regimen is proud to welcome the team responsible for a pivotal study that evaluated a pharmacy based approach to buprenorphine treatment. Today we get an exclusive behind the scenes look at the efforts that made this research possible and first-hand evidence of its impact on patients.